Title

The Study to YD312 Tablet in Patients With Diabetic Macular Edema
Multi-center, Randomized, Double-blind, Dose-finding, Phase 2a Clinical Trial to Evaluate the Effecacy and Safety of YD312 Tablet in Patients With Diabetic Macular Edema
  • Phase

    Phase 2
  • Study Type

    Interventional
  • Status

    Unknown status
  • Study Participants

    100
This study objectives is to evaluate the efficacy of YD312 to improve visual acuity in patients with diabetic macular edema (DME) compared to placebo and determine optimal dose of phase 2b study.
These study results present the possibility that imatinib can be used as a new DME inhibiting agent by involving VEGF-independent ocular angiogenesis, not action points of existing agents, in effectively inhibiting excessive vascular angiogenesis observed in oxygen-induced retinopathy.
Study Started
Oct 19
2017
Primary Completion
Jul 27
2018
Study Completion
Mar 20
2020
Anticipated
Last Update
Jan 09
2020

Drug YD312 350mg

YD312 50mg * 7 tablets

Drug Placebo

YD312 0mg * 7 tabets

Drug YD312 50mg

YD312 50mg * 1 + placebo 6 tablets

Drug YD312 150mg

YD312 50mg * 3 + placebo 6 tablets

YD312 drug treatment Experimental

From the date when dispensed, investigational products will be dosed once a day at similar time to the first dosing time with meals and much water.

YD312 placebo drug treatment Placebo Comparator

From the date when dispensed, investigational products will be dosed once a day at similar time to the first dosing time with meals and much water.

Criteria

Inclusion Criteria:

Screening Inclusion Criteria

Study subjects must be eligible for the following criteria at screening:

Subject who is male or female ≥ 19 years of age
Subject who has a diagnosis of Type 1 or 2 diabetes
Subject who has study eye with definite retinal thickening due to diabetic macular edema involving the center of the macula
Subject who has voluntarily signed an informed consent form
Randomization Inclusion Criteria

Study eye must be eligible for the following criteria at randomization:

Subject who has study eye with central subfield thickness (CST) of ≥ 300 μm on optical coherence tomography (OCT)
Subject who has study eye with an early treatment diabetic retinopathy study (ETDRS) best-corrected visual acuity (BCVA) letter score ranging from 39 to 78, inclusive (approximate Snellen equivalent of 20/32 - 20/160)

Exclusion Criteria:

Subject who has study eye with any of the following criteria:

Subject whose primary cause of macular edema is non-diabetic disease/condition (e.g., cataract extraction, vitreomacular interface abnormalities)
Subject who is expected to have no improvement of decreased visual acuity in the opinion of investigator, even if macular edema is resolved (e.g., foveal atrophy, abnormal pigmentation, dense subfoveal hard exudate)
Subject who has proliferative diabetic retinopathy.

Subject who took the following within 3 months before randomization

① Focal/grid laser photocoagulation

② Intravitreal/circumbulbar corticosteroid, anti-VEGF and pro-VEGF (but, no wash-out period is required for the corticosteroid eyedrops)

Subject who took panretinal photocoagulation (PRP) or intravitreal dexamethasone implant within 6 months before randomization
Subject who has a history of vitrectomy
Subject who took major ophthalmic surgeries (all intraocular surgeries including cataract extraction and scleral buckle) within 6 months before randomization
Subject who had systemic treatment of corticosteroid or anti-VEGF within 3 months before randomization.
Subject who administered vaccinium myrtillus extract or dobesilate calcium within 2 weeks before randomization
Subject who is suspected to require administration/treatment of drug/procedure that may affect the efficacy evaluation before the participation of clinical trial or during clinical trial (refer to '10.4 Combination Therapy and Contraindication').

Subject who has the following illness or abnormal laboratory test values:

Subject who has a hypersensitivity to any excipients of the investigational product or similar class of drug and ingredient
Subject who has uncontrolled hypertension (SBP > 160 mmHg or DBP >100 mmHg)
Subject who has uncontrolled diabetes (HbA1c > 10.0%)
Subject who has uncontrolled glaucoma in either eye (intraocular pressure (IOP) > 24 mmHg on medication or according to the investigator's judgment)
ANC < 1.5 × 109/L
Platelet < 125 × 109/L
Total bilirubin > 1.5 × ULN
AST or ALT > 2 × ULN

Clcr* < 40 mL/min

* Clcr (Cockcroft-Gault formula)

= [(140 - age) x weight(kg) (x 0.85 for females)] / [72 x serum creatinine (Scr) (mg/dL)]

Severe heart failure (NYHA class III/IV)
Malignant tumor within 5 years before randomization
Subject who is known to be HIV positive, is active hepatitis B patient or carrier, or is hepatitis C patient
Ocular inflammatory diseases such as uveitis, conjunctivitis, and blepharitis in either eye. However, the participation of subject in this study is considered at the discretion of investigator.
Unstable angina, myocardial infarction, transient ischemic attack, cerebral infarction, coronary artery bypass surgery, or transluminal coronary angioplasty within 6 months before screening

Pregnant woman, lactating woman, or female or male subject of childbearing potential

*hormonal contraceptives, intrauterne contraceptive device, sterilization of spouse (e.g., vasectomy, tubal ligation), double-barrier method (e.g., combinational use of spermicides and condoms, diaphragm, contraceptive sponge, of FemCap)

Subject who took administraion/procedure of other investigational products or medical devices within longer period between 30 days before screening or over 5time half-life.
Subject, at the discretion of the investigator, who is unsuitable to participate in the study.
No Results Posted